Third dosing cohort to be initiated in MAGE-A4 SPEAR T-cell basket study
Adaptimmune Therapeutics announced a favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A4 in the ongoing basket study in nine solid tumor indications. August 15, 2018